Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion type Assertion NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_head.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion description "[We demonstrate that HER2-specific T cells target drug resistant TICs in established OS cell lines, suggesting that incorporating immunotherapy into current treatment strategies for OS has the potential to improve outcomes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_provenance.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion evidence source_evidence_literature NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_provenance.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion SIO_000772 22173710 NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_provenance.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion wasDerivedFrom befree-2016 NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_provenance.
- NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_assertion wasGeneratedBy ECO_0000203 NP947074.RAkP5rpm9-BC3biOIPpmMSKMbQI_oeV43RnJ6A0vgcpVU130_provenance.